Bioverativ (NASDAQ:BIVV)‘s stock had its “neutral” rating reiterated by investment analysts at Credit Suisse Group in a report issued on Thursday. They currently have a $65.00 price target on the biotechnology company’s stock. Credit Suisse Group’s price target indicates a potential upside of 4.30% from the company’s previous close.
Other analysts have also recently issued reports about the stock. Jefferies Group increased their price target on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a research note on Thursday. Zacks Investment Research cut shares of Bioverativ from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the company a “hold” rating in a research note on Monday, November 20th. Morgan Stanley reissued an “underweight” rating and set a $47.00 price target (up from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Finally, Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research note on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $61.93.
Bioverativ (BIVV) traded down $1.55 on Thursday, hitting $62.32. 939,200 shares of the stock traded hands, compared to its average volume of 1,032,973. Bioverativ has a twelve month low of $40.99 and a twelve month high of $65.09.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. acquired a new position in Bioverativ in the third quarter valued at approximately $137,000. TCI Wealth Advisors Inc. acquired a new position in Bioverativ in the third quarter valued at approximately $186,000. Ladenburg Thalmann Financial Services Inc. acquired a new position in Bioverativ in the third quarter valued at approximately $190,000. Canada Pension Plan Investment Board acquired a new position in Bioverativ in the third quarter valued at approximately $194,000. Finally, ACG Wealth acquired a new position in Bioverativ in the third quarter valued at approximately $205,000. Institutional investors and hedge funds own 96.03% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Credit Suisse Group Reiterates “Neutral” Rating for Bioverativ (BIVV)” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3144173/credit-suisse-group-reiterates-neutral-rating-for-bioverativ-bivv.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.